METHODS AND RESULTS:
We recruited 2049 adults of which 651 had HF diagnosis. PCs were enumerated by flow cytometry as CD45med + blood mononuclear cells expressing CD34, CD133, vascular endothelial growth factor receptor-2, and chemokine (C-X-C motif) receptor 4 epitopes. PC subsets were lower in number in HF and after adjustment for clinical characteristics in multivariable analyses, a low CD34 + and CD34 + / CXCR + cell count remained independently associated with a diagnosis of HF (P<0.01). PC levels were not significantly different in reduced versus preserved ejection fraction patients. In 514 subjects with HF, there were 98 (19.1%) all-cause deaths during a 2.2±1. CONCLUSIONS: PC levels are lower in patients with HF, and lower PC counts are strongly and independently predictive of mortality. Strategies to increase PCs and exogenous stem cell therapies designed to improve regenerative capacity in HF, especially, in HF with preserved ejection fraction, need to be further explored.
Progenitor Cells and Clinical Outcomes in Patients With
Heart Failure P rogenitor cells (PCs) are mononuclear cells that are mostly derived from the bone marrow and can be identified in peripheral blood. CD34-expressing mononuclear cells have the potential to differentiate into diverse phenotypes, including hematopoietic, endothelial, and nonhematopoietic (mesenchymal, lacking CD45 expression) lineages and participate in vascular and myocardial regeneration.
1,2 CD133 is a 5-transmembrane antigen on primitive stem cells that is lost during maturation, and dual expression of these markers (CD34 + / CD133 + ) identifies a PC-enriched subpopulation. 3, 4 Coexpression of vascular endothelial growth factor receptor-2 (VEGFR2) seems to identify a rarer subpopulation of PCs further enriched for endothelial progenitors. 5, 6 Finally, coexpression of chemokine (C-X-C motif) receptor 4 (CXCR4), which promotes homing of PCs to stromalderived factor-rich hypoxic environments, may further characterize CD34 + PCs with capacity for tissue repair. 7 The role of PCs in myocardial regeneration and vascular repair and remodeling is recognized to be largely through angiogenic and paracrine mechanisms. 1, 8 Low circulating PC levels are associated with endothelial dysfunction, accelerated atherosclerosis, and adverse outcomes in patients with coronary artery disease and peripheral vascular disease. 9, 10 However, the role of PCs in heart failure (HF) remains controversial. Whether PC levels are altered in HF compared with appropriate control populations, whether the pathogenesis of HF differentially affects circulating PCs, and whether the alteration of PCs in HF have an impact on clinical outcomes remain unclear.
In this study, we investigated the frequency of circulating PCs enriched for hematopoietic and endothelial PCs in subjects with different types and severity of HF in comparison to non-HF controls and studied the impact of circulating PC numbers on long-term HF outcomes. Our hypothesis was that circulating PC counts will be significantly lower in patients with HF, correlate with its severity, and predict long-term outcomes in HF.
METHODS

Study Design
We enrolled patients from the Emory Cardiovascular Biobank, a prospective registry of adult patients undergoing cardiac catheterization for suspected or known coronary artery disease at 3 Emory Healthcare hospitals in Atlanta, GA. We excluded patients with (1) history of cardiac transplantation, (2) acute myocardial infarction, (3) evidence of significant infection because these would alter the levels of PC counts, and (4) patients with severe valvular disease. Demographic characteristics, medical history, medication use, and behavioral habits were documented as previously described. 9 To validate the association between HF and PC counts, we analyzed this relationship in an independent cohort of 582 subjects (137 with HF) from the MIPS (Mental Stress Ischemia Prognosis Study), a prospective study that recruited patients with stable coronary artery disease (CAD) between June 2011 and August 2014 at Emory University-affiliated hospitals as previously described. 11 Both studies were approved by the Institutional Review Board at Emory University (Atlanta, GA). All subjects provided written informed consent.
Defining HF Phenotypes
HF was defined by the presence of physician diagnosis of HF or International Classification of Diseases Ninth Revision discharge diagnosis of HF. HF was categorized into HF with reduced ejection fraction (HFrEF) with ejection fraction ≤40% and HF with preserved ejection fraction (HFpEF) with ejection fraction >40%. Ischemic cardiomyopathy was defined as presence of history of myocardial infarction, coronary revascularization, or obstructive coronary artery disease (>50% stenosis). Echocardiograms of patients with HF performed within 3 months of enrollment were reviewed for ejection fraction, diastolic dysfunction, left atrial size, left posterior wall thickness, and right ventricular systolic pressure.
PC Assays
PC assays were performed using flow cytometry as previously described 9, 10 
Follow-Up and Outcomes
We conducted follow-up as previously described 9 to identify incident adverse cardiovascular outcomes, including all-cause death, death from cardiovascular causes, and hospitalization for HF. Follow-up data were available for 495 HF patients (96.3%) with mean follow-up time of 2.17±1.47 years.
WHAT IS NEW?
• Individuals with heart failure (HF) have lower numbers of circulating hematopoietic and endothelial progenitor cells.
• Lower progenitor cell counts are associated with greater severity of HF and with higher mortality rates.
• Low endothelial-enriched progenitor cell counts are strongly associated with adverse outcomes in subjects with HF and preserved ejection fraction.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Reduced regenerative capacity, estimated as low circulating progenitor cell counts, may contribute to development and progression of HF.
• Circulating progenitor cell levels can be used an additional biomarker to identify high risk HF patients.
• Improving endogenous regenerative capacity may be a therapeutic approach for management of HF.
Statistical Analysis
Subject characteristics were reported as descriptive statistics with means, medians, standard deviations, and ranges. Differences between groups were assessed using the t test for continuous variables and χ 2 or Fischer exact tests for categorical variables where appropriate. Spearman rank correlation coefficients were used for examining associations between PCs and echocardiographic parameters, as well as BNP (B-type natriuretic peptide) levels. Two-sided P value <0.05 were considered statistically significant. For non-normally distributed variables, such as PC counts, Mann-Whitney U test was used to compare groups in unadjusted analyses. For multivariable analyses, PC counts were examined as continuous variables after log-transformation (log 2) to achieve normality. PC counts were examined also as a dichotomous variable stratified by previously identified cutoffs using receiver operating characteristic analyses and Youden index (sensitivity+specificity−1) as previously described. 9 The following cutoffs were used: 737 cells/mL for CD34 + cells, 504 cells/mL for CD34 + /CD133 + cells, 533 cells/mL for CD34 + /CXCR4 + cells, and median for CD34 + / VEGF + cells. Characteristics incorporated in multivariable analyses included variables that correlated in bivariate analysis with the outcome studied (age, sex, body mass index, smoking history, presence of CAD, ejection fraction, estimated glomerular filtration rate, β-blocker use, and angiotensin pathway antagonist use). We also used stepwise backwards regression to reach a final set of variables for each outcome, with P<0.1 as the threshold to retain a variable and obtained similar results. The association between PC count and all-cause death, cardiovascular death, HF hospitalizations adjusting for the aforementioned variables was examined in Cox regression models. Analyses were performed using IBM SPSS Statistics Version 22 (Armonk, NY).
RESULTS
Out of 1467 patients enrolled in this study, 514 had a diagnosis of HF (Table 1) . Patients with HF were more likely to be older, black, and with a higher burden of cardiovascular risk factors. Of the total HF cohort, 330 patients (64.2%) had HFrEF and 286 (86.7%) had ischemic cardiomyopathy. Patients with HFrEF were more likely to be male, black, with a history of previous myocardial infarction compared with those with HFpEF ( Table 2) . 
PCs and HF
In univariate analyses, all PC subsets were significantly lower in patients with HF except for the CD34 + /CD133 + PCs (Table 3) . After adjustment for clinical characteristics in multivariable analyses, only the CD34 + /CXCR + cell counts remained independently associated with a diagnosis of HF. Thus, a 50% decrease in CD34 + /CXCR4 + cell counts was associated with a 20% (P=0.008) increased odds of having HF (Table 3) . 
Validation Analysis
The associations between PC subsets and HF were validated in an independent cohort of 582 subjects with stable CAD enrolled in the MIPS study (Table II in the Data Supplement) in which there were significant correlations between lower PC counts and HF (Table III in the Data  Supplement) . These associations persisted after adjusting for clinical characteristics and risk factors (Table 3 ). In the pooled cohort of 2049 subjects recruited for both studies, all hematopoietic-enriched PC subsets were associated with HF (Table 3 ). The association between PC and HF persisted even after adjusting for white blood cells counts, which did not correlate with HF. (Figure 2) . This remained significant after adjusting for clinical variables in Cox regression models. Moreover, patients with PC counts below the previously reported cutoff values 9 for CD34 + , CD34 + /CD133 + , and CD34 + / CXCR4 + cell counts had a 1.8-, 1.6-, and 1.8-fold increased mortality compared with those with higher circulating PC numbers, respectively (Table 4) . We found no significant correlation between PC counts and time to first HF hospitalizations.
PCs and Severity of HF
PC Counts and Outcomes in HF
In a subgroup analysis of HFpEF patients (n=184) with 29 deaths (25 from cardiovascular causes), a low CD34 + /VEGFR2
+ cell count (median of 30 cell/mL as cutoff) was predictive of all-cause death (hazard ratio, 5.0; 95% confidence interval, 2.0-12.3; P=0.001) and cardiovascular death (hazard ratio, 4.0; 95% confidence interval, 1.6-10.0; P=0.003; Figure 3 ). Similar results were obtained with cell counts as continuous variables or as tertiles.
DISCUSSION
Novel findings of this study include (1) demonstration that compared with patients without HF, patients with HF have significantly lower circulating levels of hematopoietic-enriched PCs; (2) the magnitude of reduction in circulating levels of PC subsets correlates with the severity of HF estimated as New York Heart Association functional class, presence of diastolic dysfunction, left atrial size, pulmonary hypertension, and BNP levels; (3) patients with nonischemic cardiomyopathy have the lowest levels of CD34 + /CXCR4 + PC counts compared with all subsets of HF and non-HF patients; (4) both HFrEF and HFpEF are associated with similar reductions in the levels of circulating PCs compared with non-HF controls; (5) a low hematopoietic-enriched PC count in HF is an independent predictor of higher mortality; and (6) a low endothelial-enriched PC count is predictive of adverse outcomes in the HFpEF but not in the HFrEF population.
Conflicting relationships between circulating PC numbers and HF have been published. [12] [13] [14] [15] [16] Possible reasons for this inconsistency include the small numbers of subjects studied (the largest study included 128 patients), comparisons with inappropriate controls, variations in phenotyping of PCs with use of functional assays or limited flow cytometry, and the differences in HF phenotypes studied. In contrast, herein we report the results of over 650 patients who were carefully phenotyped for pathogenesis and severity of HF who were compared with over 1400 appropriate controls, and use of standardized and detailed flow cytometric analysis using an array of specific hematopoietic and endothelial PC markers. Similar to CAD, PCs in ischemic HF are numerically and functionally impaired. However, functional exhaustion in the bone marrow, impaired mobilization or incorporation into damaged tissues, and reduced half-life of PCs may contribute to an unfavorable left ventricular remodeling and adverse outcomes in patients with HF 17 . Similarly, conflicting results have been reported regarding the correlation between levels of PCs and severity of HF. 12, 18, 19 Interestingly, our study shows discor- dant behavior of PC subpopulations in HF patients. We observed a progressive decline in endothelial-enriched, VEGFR2-expressing PC counts, with >3-fold decrease in counts in advanced HF (New York Heart Association IV class), while PC subsets enriched for hematopoietic PCs did not show significant changes. Further, we found correlations between BNP and PCs demonstrating that subjects with higher BNP values had lower levels of both hematopoietic and endothelial-enriched PCs. These findings have also been controversial in some previous studies. 12, 13, 20 Our study also illustrated an association between PC counts and estimated pulmonary artery pressure. Previous studies investigating the role of PCs in patients with pulmonary arterial hypertension have yielded conflicting results 21, 22 that may be explained by the differences in the etiologies or stages of pulmonary arterial hypertension. Together, the association with functional class measures, BNP, and pulmonary hypertension suggest that subjects with more severe HF are likely to have lower levels of circulating PCs.
In agreement with previous observations, both HFrEF and HFpEF were associated with similar reductions in levels of circulating PCs compared with non-HF controls. 14, 23 Several studies have reported that patients with nonischemic cardiomyopathy have higher levels of circulating hematopoietic and endothelial origin PCs, 24, 25 whereas others have reported lower PC numbers in this group. 26 In the present study, we demonstrate a significant decrease in the CD34 + /CXCR4 + PC subset in patients with nonischemic cardiomyopathy, suggesting a potential pathophysiologic role of PCs and possibly the CXCR4/stromal-derived factor homing axis in nonischemic cardiomyopathy.
There are several potential mechanisms by which PCs may contribute to disease progression and outcomes in patients with HF. Experimental studies have shown that low levels of PCs are associated with impaired endogenous regeneration and repair capacity. 2 These studies have also demonstrated several ways in which PCs may reduce further deterioration in HF. PCs mitigate adverse left ventricular remodeling after infarction, prevent apoptosis of cardiomyocytes by secreting insulin growth factor-1, stimulate angiogenesis by either direct incorporation of the cells into the expanding vasculature or more likely through paracrine secretion of angiogenic growth factors (vascular endothelial growth factor and basic fibroblast growth factor) and exosomes that support the developing microvasculature, help activate cardiac and other resident stem cells, and recruit additional local PCs. 17, 27 Reduced PC counts may also be a marker of advanced HF because of several factors, such as malnutrition, cardiac cachexia, cardio-renal syndrome, renin-angiotensin system activation, altered endothelial nitric oxide synthase activity, or activation of proinflammatory cytokines, leading to bone marrow suppression.
Importantly, we found that lower PC counts are independent predictors of increased mortality. Previous studies have shown that reduced PC counts are associated with worse clinical outcomes in patients with coronary and peripheral vascular disease, 9,10 but results in HF populations have remained controversial as studies have been mostly in small populations, with predominantly HFrEF and short-term follow-up. 23, 28, 29 Previous studies have also often used culture assays to quantify PCs that remain controversial measures of regenerative capacity. In contrast, we have studied >500 patients with both HFrEF and HFpEF who have undergone extensive phenotyping of hematopoietic and endothelial PCs and have detailed long-term follow-up for determination of hard HF outcomes.
An important observation in our study was the association of HFpEF outcomes with the reduction in endothelial progenitors. This relationship may be because of the known association between nitric oxide deficiency and HFpEF. For example, reduced endothelial-enriched PC activity accompanies endothelial dysfunction. 30 Several studies have demonstrated the association between endothelial dysfunction and the presence and progression of HFpEF. 31 Experimental studies have shown that endothelial nitric oxide synthase knockout mice have concentric left ventricular hypertrophy and greater diastolic dysfunction after abdominal aortic banding compared with wild-type mice, indicating the role of nitric oxide in left ventricular remodeling and development of HFpEF. 32 Finally, nitric oxide seems to be pivotal in the mobilization of PCs from the bone marrow. 33 Together these findings suggest that impaired mobilization of endothelial-enriched PCs, likely associated with reduced nitric oxide bioavailability, contributes to the development and progression of HFpEF.
Limitations of our study are that we examined a population undergoing angiography, and therefore, our conclusions may not be applicable to other HF subtypes, including valvular HF. Absence of functional assessments of circulating PCs also limits the conclusions that could be drawn about the proliferative and angiogenic capacity of the lower numbers of PCs, but previous studies have shown correlations between PC numbers and proliferative potential. 34 Most of the participants in this study had CAD, and so the results may not be applicable to individuals without CAD. Finally, the observational nature of this analysis does not imply causation, and thus, longer term follow-up and interventional studies directly influencing PC levels are required.
In conclusion, by examining circulating levels of hematopoietic and endothelial PC subsets, we show that PC levels are not only predictive of prevalent HF, whether it is HFrEF or HFpEF, but also of outcomes in HF. In this regard, we have provided more definitive data on the unique contribution of PC physiology to the syndrome of HF and its outcomes. These insights are especially important for those with HFpEF where there seems to be a unique role for endothelial-enriched PC populations. 
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